Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.
Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.